Medical Care Technologies Inc. Introduces AI-Powered Facial Analysis for Diabetic Retinopathy Detection

Rhea-AI Summary

Medical Care Technologies (OTC:MDCE) has launched an innovative AI Facial Health Risk Estimator designed to detect diabetic retinopathy in its early stages. The technology analyzes facial images to identify retinal abnormalities such as microaneurysms, hemorrhages, and vascular leakage, offering a non-invasive screening solution.

CEO Marshall Perkins emphasized that this AI-powered system aims to address the challenge of late diagnosis in diabetic retinopathy, which is a leading cause of preventable blindness globally. The technology promises to improve accessibility to early screening and enhance patient outcomes through early detection.

Positive

• Introduction of innovative AI technology for early diabetic retinopathy detection
• Non-invasive screening method increases accessibility
• Addresses a significant global health issue (preventable blindness)

Negative

• No clinical validation data provided
• No regulatory approval status mentioned

MESA, ARIZONA / ACCESS Newswire / September 26, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE) unveiled its AI Facial Health Risk Estimator for early detection of diabetic retinopathy, a leading cause of preventable blindness worldwide.

The system analyzes subtle retinal cues captured from standard facial imaging, identifying microaneurysms, hemorrhages, and vascular leakage, allowing for non-invasive, accessible early screening.

"Diabetic retinopathy often goes undiagnosed until vision loss occurs," said Marshall Perkins, CEO of MDCE. "Our AI technology allows earlier detection, broader screening access, and better patient outcomes."

Company Websites: www.medicalcaretechnologies.com | www.mdcestock.com

About Medical Care Technologies Inc.
Medical Care Technologies Inc. (OTC PINK: MDCE) is at the forefront of AI-driven preventive healthcare, providing early detection tools across systemic, ocular, and dermatological conditions.

Safe Harbor Statement:
Forward-looking statements are included in this release. Risks and uncertainties may cause actual results to differ materially.

Contact:

Investor Relations
Medical Care Technologies Inc.
info@infiniteauctions.com
Website: www.mdcestock.com

SOURCE: Medical Care Technologies Inc. (OTC PINK:MDCE)

View the original press release on ACCESS Newswire

FAQ

What is Medical Care Technologies' (MDCE) new AI technology for diabetic retinopathy?

MDCE has launched an AI Facial Health Risk Estimator that analyzes facial images to detect early signs of diabetic retinopathy by identifying microaneurysms, hemorrhages, and vascular leakage.

How does MDCE's AI Facial Health Risk Estimator work?

The system uses AI to analyze subtle retinal cues from standard facial imaging, detecting signs of diabetic retinopathy such as microaneurysms, hemorrhages, and vascular leakage in a non-invasive manner.

What problem does MDCE's new AI technology solve?

The technology addresses the late diagnosis of diabetic retinopathy, which often goes undetected until vision loss occurs, by providing early, accessible screening options.

Who is the CEO of Medical Care Technologies (MDCE)?

Marshall Perkins is the CEO of Medical Care Technologies (MDCE).

What are the potential benefits of MDCE's AI screening technology?

The technology offers non-invasive early detection, broader screening accessibility, and improved patient outcomes for diabetic retinopathy, a leading cause of preventable blindness.